Physician profile
Thomas Joseph
NPI 1710419213
$3,660.93
in general payments reported to CMS, 2019-2025
22 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $581 · 2022: $751 · 2023: $938 · 2024: $1,005 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $942.79 | 2022-2025 | Dyanavel Xr |
| Abbvie INC. | $575.47 | 2021-2024 | |
| Alkermes, INC. | $510.86 | 2021-2024 | Lybalvi |
| Janssen Pharmaceuticals, INC | $509.66 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $216.41 | 2021-2023 | Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $139.90 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $138.11 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $134.87 | 2022-2024 | Austedo Xr |
| Indivior INC. | $76.60 | 2021-2024 | Perseris |
| Almatica Pharma LLC | $69.22 | 2021-2024 | Loreev Xr, Gralise |
| Ironshore Pharmaceuticals INC. | $57.66 | 2022-2024 | |
| Axsome Therapeutics, INC. | $41.46 | 2024 | Auvelity |
| Neurocrine Biosciences, INC. | $39.38 | 2022-2023 | Ingrezza |
| Validus Pharmaceuticals LLC | $37.80 | 2023 | Equetro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.63 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.35 | 2023 | Xywav |
| Alfasigma USA, INC. | $21.74 | 2021 | |
| Lundbeck LLC | $20.68 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.49 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.14 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.01 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.70 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.